Therapeutic for Alzheimer's disease shows improved safety profile
In a direct comparison, ProMIS Neurosciences’ oligomer-selective antibody (PMN310) reveals a potential advantage over other antibody therapeutics for Alzheimer's disease.
Please sign in or register for FREE
Sign in to MedChemNet
Register to MedChemNet
MedChemNet is a communal space where industry and academic professionals can come together to discuss the latest research and developments, share thoughts and opinions, and build valuable international relationships.